- Home
- EYPT vs OMCL Comparison
EYPT vs OMCL Comparison
Compare EYPT & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | OMCL |
|---|---|---|
| Founded | 1987 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Computer Manufacturing |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.5B |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | EYPT | OMCL |
|---|---|---|
| Price | $14.70 | $37.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $31.80 | ★ $53.67 |
| AVG Volume (30 Days) | ★ 795.3K | 381.6K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | $7,539,000.00 | ★ $787,309,000.00 |
| Revenue This Year | N/A | $6.77 |
| Revenue Next Year | $3,115.57 | $5.22 |
| P/E Ratio | ★ N/A | $938.75 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $5.44 | $22.66 |
| 52 Week High | $19.11 | $51.84 |
Technical Indicators
Market Signals| Indicator | EYPT | OMCL |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 58.58 |
| Support Level | $14.50 | $32.20 |
| Resistance Level | $18.99 | $42.60 |
| Average True Range (ATR) | 0.66 | 1.39 |
| MACD | 0.25 | 0.67 |
| Stochastic Oscillator | 92.13 | 95.12 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.